A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy
Status:
Not yet recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2a multicenter study, which consists of two parts:
Part 1: the Phase 1b part of the study will investigate the safety of the combination of
ATX-101 with carboplatin/pegylated liposomal doxorubicin (ACD). ATX-101 will be administered
intravenously in three escalation cohorts: 20, 30, and 45 mg/m² according to a 3+3 design. In
the case where 20 mg/m² is not tolerated, the dose can be de-escalated to 15 mg/m².
Part 2: the Phase 2a part of the study will investigate the efficacy and safety of ACD.
ATX-101 will be administered at the dose defined in Part 1 of the study.
Treatment will continue up to six cycles or until disease progression or unacceptable
toxicity, participant withdrawal of consent, non-compliance, lost to follow-up, or withdrawal
at the Investigators discretion, whichever occurs first.